Cerus
CERS
$1.69
Share price
-6.63%
Change (1 day)
-34.24%
Change (1 year)
Categories
P/S ratio for Cerus (CERS)
P/S ratio as of June 2024 (TTM): 2.04
According to Cerus's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.04357. At the end of 2023 the company had a P/S ratio of 2.50.
P/S ratio history for Cerus from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 2.50 | -37.37% |
| 2022 | 4.00 | -55.78% |
| 2021 | 9.04 | -28.61% |
| 2020 | 12.7 | 55.21% |
| 2019 | 8.16 | -28.4% |
| 2018 | 11.4 | 27.07% |
| 2017 | 8.96 | -25.94% |
| 2016 | 12.1 | -33.86% |
| 2015 | 18.3 | 32.83% |
| 2014 | 13.8 | 17.88% |
| 2013 | 11.7 | 140.67% |
| 2012 | 4.86 | 19.15% |
| 2011 | 4.08 | -19.1% |
| 2010 | 5.04 | 17.71% |
| 2009 | 4.28 | 210.57% |
| 2008 | 1.38 | -93.08% |
| 2007 | 19.9 | 281.23% |
| 2006 | 5.23 | -44.12% |
| 2005 | 9.35 | 98.58% |
| 2004 | 4.71 | -54.55% |
| 2003 | 10.4 | -74.34% |
| 2002 | 40.4 | -74.56% |
| 2001 | 159 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Boston Scientific BSX | 7.62 | 272.70% | 🇺🇸 USA |
 Utah Medical Products UTMD | 4.80 | 135.10% | 🇺🇸 USA |
 Haemonetics HAE | 3.33 | 63.02% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 92.7 | 4,435.26% | 🇺🇸 USA |